Cellular therapies against solid tumors face three major barriers: low persistence, insufficient specificity, and high costs. In a recent study, Pal et al. tackle these challenges in kidney cancer by using novel, 'persistence-tuned' allogeneic chimeric antigen receptor (CAR) T cells directed against a stable antigen.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tips.2024.07.002 | DOI Listing |
Publication Analysis
Top Keywords
'living drugs'
4
drugs' target
4
target cd70
4
cd70 advanced
4
advanced renal
4
renal tumors
4
tumors cellular
4
cellular therapies
4
therapies solid
4
solid tumors
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!